Author BioSketch

Jong Chul Park, MD, is a Clinical Fellow working in the Genitourinary Cancer Research Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, USA. He received his medical degree from Seoul National University, South Korea. Dr. Park completed his medical oncologist fellowship at Lombardi Comprehensive Cancer Center at Georgetown University. His research interest is genitourinary oncology. Deborah E. Citrin, MD, is a clinical and translational researcher and radiation oncologist at the National Cancer Institute in Bethesda, MD. She joined the National Cancer Institute in 2001 and has served in her current position since 2007. Her clinical and laboratory research interests center around the preclinical and clinical exploration of novel radiation modifiers and in further understanding normal tissue injury from irradiation. Piyush K. Agarwal, MD, is a tenure-track investigator and the Head of the Bladder Cancer Section in the Urologic Oncology Branch of the National Cancer Institute, National Institutes of Health in Bethesda, MD. He received his M.D. from the Cornell (Weill) University School of Medicine in New York, New York. He then completed his urology residency at Case Western Reserve University in Cleveland, Ohio. He then went on to the University of Texas MD Anderson Cancer Center where he completed a fellowship in urologic oncology. Before coming to the NIH, Dr. Agarwal was a faculty member at the Henry Ford Hospital Vattikuti Urology Institute where he served as the Director of Robotic Bladder Surgery. Dr. Agarwal is a board-certified and fellowship-trained Urologic Oncologic Surgeon. He specializes in multidisciplinary management of bladder cancer and complex surgical techniques, including robotic cystectomy and continent urinary diversions. He is also an expert in other urologic cancers including prostate, testicular, and penile carcinoma. His clinical and laboratory research focus on all aspects of bladder cancer, specifically, BCGrefractory disease and molecular targeted therapy. Andrea B. Apolo, MD, is a Lasker Clinical Research Scholar, Tenure-Track Investigator, and Chief of the Bladder Cancer Section in the Genitourinary Malignancies Branch of the National Cancer Institute (NCI). She is a boardcertified medical oncologist with expertise in clinical and translational research in genitourinary malignancies, particularly urothelial cancer. She received her M.D. from Albert Einstein College of Medicine in New York. She then completed an internal medicine residency at New YorkPresbyterian Hospital/Weill Cornell Medical Center followed by a medical oncology fellowship at Memorial Sloan Kettering Cancer Center. Dr. Apolo then joined the Medical Oncology Branch of the National Cancer Institute with the charge of developing a bladder cancer program in the intramural NCI. Her research involves developing and designing clinical trials to test new bladder cancer therapies that use targeted and immunotherapeutic strategies. She is also interested in improving our understanding of critical signaling pathways in urothelial carcinoma, including the MET pathway, which may serve as a therapeutic target in patients with multidrug-resistant disease. Curr Probl Cancer, May/June 2014

79